Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based biotechnology company HST Global has announced that it has, through its contracted partner EBITDA Capital of Newport Beach California and its group of associates, started negotiations with the Chinese Government for both direct investment and a license for treatment protocols.
Subscribe to our email newsletter
Ron Howell, CEO and president of HST Global, said: “Through the use of the EBITDA Capital resources we at HST Global can focus on the issue of bringing awareness of our treatment and solution for late stage cancer treatment to the Chinese community.
“We want to ensure that our treatment is being given every opportunity to be recognized as the medical solution alternative of choice throughout the world.”